These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23817592)

  • 1. Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer.
    Yoshii H; Ito K; Asano T; Horiguchi A; Hayakawa M; Asano T
    Oncol Rep; 2013 Sep; 30(3):1073-80. PubMed ID: 23817592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual role of TGFBR3 in bladder cancer.
    Liu XL; Xiao K; Xue B; Yang D; Lei Z; Shan Y; Zhang HT
    Oncol Rep; 2013 Sep; 30(3):1301-8. PubMed ID: 23835618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.
    Behnsawy HM; Miyake H; Abdalla MA; Sayed MA; Ahmed Ael-F; Fujisawa M
    Urol Oncol; 2011; 29(5):495-501. PubMed ID: 19914103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
    Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Salmas M; Malamou-Mitsi V
    BJU Int; 2005 Mar; 95(4):655-9. PubMed ID: 15705098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
    Zhang Z; Zhang G; Kong C
    Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological growth pattern of and alpha-actinin-4 expression in thyroid cancer.
    Tanaka N; Yamashita T; Yamamoto S; Matsunobu T; Tsuda H; Honda K; Yamada T; Tamai S; Shiotani A
    Anticancer Res; 2014 Jun; 34(6):3157-63. PubMed ID: 24922688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
    Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection.
    Muramaki M; Miyake H; Terakawa T; Kumano M; Sakai I; Fujisawa M
    Urol Oncol; 2012; 30(2):161-6. PubMed ID: 20451421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy.
    Hassan JM; Cookson MS; Smith JA; Johnson DL; Chang SS
    J Urol; 2004 Sep; 172(3):882-4. PubMed ID: 15310989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
    Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.